Roche has announced the launch of its new analytical units, cobas c 703 and cobas ISE neo, for the cobas pro integrated solutions, in countries accepting the CE mark. The cobas pro integrated solutions is a scalable and modular diagnostic platform designed for high-volume laboratories. These analytical units offer ‘cutting-edge’ features to help address some of the key challenges faced by diagnostic laboratories worldwide such as shortage of qualified staff and space limitations.
“Today more than ever, accurate and timely diagnostics is critical for effective delivery of healthcare. Labs are under increasing pressure to process more samples, at greater speed without compromising on accuracy,” said Matt Sause, CEO of Roche Diagnostics. “With the launch of the cobas c 703 and cobas ISE neo, we are taking our latest generation clinical chemistry and immunochemistry platform, the cobas pro integrated solutions, to the next level. By integrating high-volume clinical chemistry testing and increased automation, we will set a new standard for high volume testing in the clinical lab.”
With cobas pro integrated solutions, the required sample volume per test has been reduced on average by 43% compared to previous generation systems. Additionally, the plastic generated per test result has been reduced by up to 78% due to smaller reagent pack sizes and a higher number of tests per pack.
Designed to seamlessly integrate into clinical chemistry and immunochemistry testing, Roche’s innovative mass spectrometry analyser will also be available as part of the cobas pro integrated solutions in the near future.